DRUG-CLASS OVERVIEW:@0.982174:0.513429:0.982174:0.311367:0.954164:0.311367:0.954164:0.513429:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.233372:0.041064:0.000000:0.000000:0.019473
191:@0.945393:0.038601:0.984904:0.038601:0.984904:0.019004:0.945393:0.019004:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
7. SMALL-MOLECULE KINASE :@0.084848:0.079411:0.405641:0.079411:0.405641:0.059814:0.084848:0.059814:0.013170:0.006585:0.006585:0.012230:0.021167:0.017404:0.010348:0.010348:0.009878:0.021167:0.019756:0.010348:0.012230:0.018344:0.015052:0.010348:0.012230:0.006585:0.014581:0.006585:0.017404:0.017404:0.012230:0.012230:0.006585
INHIBITORS:@0.084848:0.098797:0.207144:0.098797:0.207144:0.079201:0.084848:0.079201:0.006585:0.017404:0.015993:0.006585:0.013641:0.006585:0.009878:0.019756:0.013641:0.012230
Dasatinib, imatinib and nilotinib:@0.084848:0.117869:0.409404:0.117869:0.409404:0.100054:0.084848:0.100054:0.014966:0.014111:0.009407:0.014111:0.006414:0.005131:0.012828:0.005131:0.014111:0.005987:0.005987:0.005131:0.020098:0.014111:0.006414:0.005131:0.012828:0.005131:0.014111:0.005987:0.014111:0.012828:0.014111:0.005987:0.012828:0.005131:0.005131:0.013683:0.006414:0.005131:0.012828:0.005131:0.014111
Imatinib is a two-phenylaminopyrimidine :@0.084848:0.134731:0.481069:0.134731:0.481069:0.118975:0.084848:0.118975:0.004349:0.018049:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.010468:0.003848:0.007466:0.010468:0.013143:0.010468:0.006523:0.015990:0.012604:0.006388:0.013123:0.011738:0.012508:0.011738:0.010314:0.003848:0.013143:0.018049:0.003848:0.011738:0.012604:0.013123:0.010314:0.005792:0.003848:0.018049:0.003848:0.013181:0.003848:0.011738:0.012508:0.005330
derivative tyrosine kinase inhibitor, which :@0.084848:0.150448:0.481084:0.150448:0.481084:0.134692:0.084848:0.134692:0.013181:0.012508:0.005792:0.003848:0.010660:0.013143:0.006523:0.003848:0.010660:0.012508:0.009256:0.006523:0.010314:0.005711:0.012604:0.007466:0.003848:0.011738:0.012508:0.009256:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.009256:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.003772:0.005330:0.009256:0.015990:0.011738:0.003848:0.012450:0.011738:0.005330
inhibits the tyrosine kinase domain of the :@0.084848:0.166164:0.481103:0.166164:0.481103:0.150408:0.084848:0.150408:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.007466:0.007832:0.006523:0.011738:0.012508:0.007820:0.006523:0.010314:0.005713:0.012604:0.007466:0.003848:0.011738:0.012508:0.007832:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.007832:0.013181:0.012604:0.018049:0.013143:0.003848:0.011738:0.007832:0.012604:0.006042:0.007822:0.006523:0.011738:0.012508:0.005330
Bcr-Abl oncoprotein in CML.:@0.084848:0.181880:0.352955:0.181880:0.352955:0.166124:0.084848:0.166124:0.011045:0.012450:0.005792:0.006388:0.014239:0.013123:0.003848:0.007551:0.012604:0.011738:0.012450:0.012604:0.013114:0.005713:0.012604:0.006523:0.012508:0.003848:0.011738:0.007543:0.003848:0.011738:0.007549:0.015644:0.017684:0.008890:0.005330
4,26:@0.352949:0.176260:0.374702:0.176260:0.374702:0.167075:0.352949:0.167075:0.006215:0.003107:0.006215:0.006215
 Imatinib is :@0.374707:0.181879:0.481085:0.181879:0.481085:0.166123:0.374707:0.166123:0.007549:0.004349:0.018049:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.007562:0.003848:0.007466:0.005330
also capable of inhibiting tyrosine kinase :@0.084839:0.197595:0.481058:0.197595:0.481058:0.181839:0.084839:0.181839:0.013143:0.003848:0.007466:0.012604:0.008313:0.012450:0.013143:0.013123:0.013143:0.013123:0.003848:0.012508:0.008313:0.012604:0.006042:0.008313:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.003848:0.011738:0.012950:0.008313:0.006523:0.010314:0.005713:0.012604:0.007466:0.003848:0.011738:0.012508:0.008313:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.005330
receptors  such  as PDGF,  stem-cell factor :@0.084839:0.213312:0.481102:0.213312:0.481102:0.197556:0.084839:0.197556:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.007466:0.005330:0.003327:0.007466:0.011699:0.012450:0.011738:0.005330:0.003335:0.013143:0.007466:0.008678:0.011392:0.014316:0.016779:0.006981:0.005330:0.005330:0.003335:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.008678:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.005330
and c-Kit in GI stromal tumours (GIST).:@0.084839:0.229028:0.431789:0.229028:0.431789:0.213272:0.084839:0.213272:0.013143:0.011738:0.013181:0.005330:0.012450:0.006388:0.011372:0.003848:0.006523:0.005330:0.003848:0.011738:0.005330:0.016779:0.004349:0.005330:0.007466:0.006523:0.005705:0.012604:0.018049:0.013143:0.003848:0.005330:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.007100:0.016779:0.004349:0.009583:0.008197:0.007100:0.005330
4,26:@0.431785:0.223408:0.453537:0.223408:0.453537:0.214222:0.431785:0.214222:0.006215:0.003107:0.006215:0.006215
 :@0.453542:0.229027:0.458872:0.229027:0.458872:0.213271:0.453542:0.213271:0.005330
CML is a clonal pluripotent haematopoi-:@0.103022:0.244743:0.475763:0.244743:0.475763:0.228987:0.103022:0.228987:0.015644:0.017684:0.008890:0.004682:0.003848:0.007466:0.004695:0.013143:0.004695:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.004686:0.013123:0.003848:0.011699:0.005792:0.003848:0.013123:0.012604:0.006523:0.012508:0.011738:0.006523:0.004676:0.011738:0.013143:0.012508:0.018049:0.013143:0.006523:0.012604:0.013123:0.012604:0.003848:0.006388
etic  stem-cell disorder.   CML  contains  a :@0.084838:0.260459:0.481086:0.260459:0.481086:0.244703:0.084838:0.244703:0.012508:0.006523:0.003848:0.012450:0.005330:0.003972:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.009313:0.013181:0.003848:0.007466:0.012604:0.005678:0.013181:0.012508:0.004378:0.005330:0.012437:0.005330:0.003974:0.015644:0.017684:0.008890:0.005330:0.003970:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.007466:0.005330:0.003970:0.013143:0.622857
42:@0.300548:0.254840:0.312978:0.254840:0.312978:0.245654:0.300548:0.245654:0.006215:0.006215
derivate chromosome known as the Phila-:@0.084844:0.276175:0.475752:0.276175:0.475752:0.260419:0.084844:0.260419:0.013181:0.012508:0.005792:0.003848:0.010660:0.013143:0.006523:0.012508:0.005099:0.012450:0.011738:0.005711:0.012604:0.018049:0.012604:0.007466:0.012604:0.018049:0.012508:0.005099:0.009660:0.011738:0.012604:0.015990:0.011728:0.005099:0.013143:0.007466:0.005111:0.006523:0.011738:0.012508:0.005099:0.011392:0.011738:0.003848:0.003848:0.013143:0.006388
delphia chromosome.  Here, a balanced :@0.084844:0.291891:0.481081:0.291891:0.481081:0.276135:0.084844:0.276135:0.013181:0.012508:0.003848:0.013123:0.011738:0.003848:0.013143:0.005638:0.012450:0.011738:0.005709:0.012604:0.018049:0.012604:0.007466:0.012604:0.018049:0.012508:0.005330:0.012420:0.005625:0.013143:0.012508:0.005713:0.012508:0.005330:0.005621:0.013143:0.005626:0.013123:0.013143:0.003848:0.013143:0.011738:0.012450:0.012508:0.013181:0.577143
42:@0.290968:0.286272:0.303398:0.286272:0.303398:0.277086:0.290968:0.277086:0.006215:0.006215
translocation between the c-Abl gene on :@0.084847:0.307607:0.481093:0.307607:0.481093:0.291851:0.084847:0.291851:0.006523:0.005792:0.013143:0.011738:0.007466:0.003848:0.012604:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005944:0.013123:0.012508:0.006523:0.015990:0.012508:0.012508:0.011738:0.005946:0.006523:0.011738:0.012508:0.005948:0.012450:0.006388:0.014239:0.013123:0.003848:0.005954:0.012950:0.012508:0.011738:0.012508:0.005944:0.012604:0.011738:0.005330
chromosome 9 and the Bcr gene on chro-:@0.084847:0.323323:0.475764:0.323323:0.475764:0.307567:0.084847:0.307567:0.012450:0.011738:0.005709:0.012604:0.018049:0.012604:0.007466:0.012604:0.018049:0.012508:0.005061:0.010660:0.005061:0.013143:0.011738:0.013181:0.005061:0.006523:0.011738:0.012508:0.005061:0.011045:0.012450:0.005792:0.005061:0.012950:0.012508:0.011738:0.012508:0.005061:0.012604:0.011738:0.005061:0.012450:0.011738:0.005709:0.012604:0.006388
mosome 22 is found on a single chromo-:@0.084847:0.339039:0.475757:0.339039:0.475757:0.323283:0.084847:0.323283:0.018049:0.012604:0.007466:0.012604:0.018049:0.012508:0.007472:0.010660:0.010660:0.007485:0.003848:0.007466:0.007485:0.006042:0.012604:0.011699:0.011738:0.013181:0.007472:0.012604:0.011738:0.007472:0.013143:0.007485:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.007485:0.012450:0.011738:0.005709:0.012604:0.018049:0.012592:0.006388
some as a chimeric Bcr-Abl gene which is :@0.084847:0.354756:0.481068:0.354756:0.481068:0.339000:0.084847:0.339000:0.007466:0.012604:0.018049:0.012508:0.006023:0.013143:0.007466:0.006023:0.013143:0.006023:0.012450:0.011738:0.003848:0.018049:0.012508:0.005792:0.003848:0.012450:0.006023:0.011045:0.012450:0.005792:0.006388:0.014239:0.013123:0.003848:0.006023:0.012950:0.012508:0.011738:0.012508:0.006023:0.015990:0.011738:0.003848:0.012450:0.011738:0.006023:0.003848:0.007466:0.005330
responsible for CML.:@0.084847:0.370472:0.271439:0.370472:0.271439:0.354716:0.084847:0.354716:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.003848:0.013123:0.003848:0.012508:0.005330:0.006042:0.012604:0.005792:0.005330:0.015644:0.017684:0.008890:0.005330
4,42:@0.271428:0.364851:0.293180:0.364851:0.293180:0.355666:0.271428:0.355666:0.006215:0.003107:0.006215:0.006215
Similar to imatinib, dasatinib and nilotin-:@0.103030:0.386186:0.475756:0.386186:0.475756:0.370430:0.103030:0.370430:0.009583:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.006292:0.006523:0.012604:0.006277:0.003848:0.018049:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.006283:0.013181:0.013143:0.007466:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.006292:0.013143:0.011738:0.013181:0.006279:0.011738:0.003848:0.003848:0.012604:0.006523:0.003848:0.011738:0.006388
ib inhibit the same tyrosine kinase and ki-:@0.084846:0.401903:0.475773:0.401903:0.475773:0.386147:0.084846:0.386147:0.003848:0.013123:0.007197:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.007197:0.006523:0.011738:0.012508:0.007175:0.007466:0.013143:0.018049:0.012508:0.007197:0.006523:0.010314:0.005711:0.012604:0.007466:0.003848:0.011738:0.012508:0.007183:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.007187:0.013143:0.011738:0.013181:0.007185:0.009660:0.003848:0.006388
nase  receptor,  but  differ  from  imatinib in :@0.084846:0.417619:0.481093:0.417619:0.481093:0.401863:0.084846:0.401863:0.011738:0.013143:0.007466:0.012508:0.005330:0.003106:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.003762:0.005330:0.005330:0.003102:0.013123:0.011699:0.006523:0.005330:0.003102:0.013181:0.003848:0.006102:0.006042:0.012508:0.005792:0.005330:0.003098:0.006042:0.005711:0.012604:0.018049:0.005330:0.003104:0.003848:0.018049:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.008447:0.003848:0.011738:0.005330
that they bind to the active and inactive :@0.084846:0.433335:0.481095:0.433335:0.481095:0.417579:0.084846:0.417579:0.006523:0.011738:0.013143:0.006523:0.006889:0.006523:0.011738:0.012508:0.010314:0.006889:0.013123:0.003848:0.011738:0.013181:0.006889:0.006523:0.012604:0.006879:0.006523:0.011738:0.012508:0.006889:0.013143:0.012450:0.006523:0.003848:0.010660:0.012508:0.006889:0.013143:0.011738:0.013181:0.006889:0.003848:0.011738:0.013143:0.012450:0.006523:0.003848:0.010660:0.012508:0.005330
conforms of the Abl kinase domain, over-:@0.084846:0.449051:0.475736:0.449051:0.475736:0.433295:0.084846:0.433295:0.012450:0.012604:0.011738:0.006042:0.012604:0.006312:0.018049:0.007466:0.006465:0.012604:0.006042:0.006465:0.006523:0.011738:0.012508:0.006465:0.014239:0.013123:0.003848:0.006465:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.006465:0.013181:0.012604:0.018049:0.013143:0.003848:0.011738:0.005330:0.006465:0.012604:0.010660:0.012508:0.005792:0.006388
coming imatinib resistance due to muta-:@0.084846:0.464767:0.475734:0.464767:0.475734:0.449012:0.084846:0.449012:0.012450:0.012604:0.018049:0.003848:0.011738:0.012950:0.007889:0.003848:0.018049:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.007889:0.005713:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.012450:0.012508:0.007889:0.013181:0.011699:0.012508:0.007889:0.006523:0.012604:0.007889:0.018049:0.011699:0.006523:0.013143:0.006388
tions in the Bcr-Abl kinase.:@0.084846:0.480484:0.329513:0.480484:0.329513:0.464728:0.084846:0.464728:0.006523:0.003848:0.012604:0.011738:0.007466:0.006388:0.003848:0.011738:0.006388:0.006523:0.011738:0.012508:0.006388:0.011045:0.012450:0.005792:0.006388:0.014239:0.013123:0.003848:0.006388:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.005330
4,26:@0.329515:0.474863:0.351268:0.474863:0.351268:0.465677:0.329515:0.465677:0.006215:0.003107:0.006215:0.006215
 Furthermore, :@0.351273:0.480482:0.481093:0.480482:0.481093:0.464726:0.351273:0.464726:0.006388:0.009333:0.011699:0.005792:0.006523:0.011738:0.012508:0.006312:0.018049:0.012604:0.005707:0.012508:0.005330:0.005330
research has shown that dasatinib is much :@0.084842:0.496198:0.481072:0.496198:0.481072:0.480442:0.084842:0.480442:0.005713:0.012508:0.007466:0.012508:0.013143:0.005657:0.012450:0.011738:0.004772:0.011738:0.013143:0.007466:0.004772:0.007466:0.011738:0.012604:0.015990:0.011738:0.004772:0.006523:0.011738:0.013143:0.006523:0.004772:0.013181:0.013143:0.007466:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.004772:0.003848:0.007466:0.004784:0.018049:0.011699:0.012450:0.011738:0.005330
more  potent  compared  to  imatinib :@0.084842:0.511914:0.481070:0.511914:0.481070:0.496158:0.084842:0.496158:0.018049:0.012604:0.005709:0.012508:0.005330:0.015921:0.013123:0.012604:0.006523:0.012508:0.011738:0.006523:0.005330:0.015910:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.005330:0.015923:0.006523:0.012604:0.005330:0.015915:0.003848:0.018049:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330
against Bcr-Abl-expressing cells.:@0.084842:0.527631:0.379597:0.527631:0.379597:0.511875:0.084842:0.511875:0.013143:0.012950:0.013143:0.003848:0.011738:0.007466:0.006523:0.005330:0.011045:0.012450:0.005792:0.006388:0.014239:0.013123:0.003848:0.006388:0.012508:0.009236:0.013123:0.005715:0.012508:0.007466:0.007466:0.003848:0.011738:0.012950:0.005330:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330
26:@0.379611:0.522011:0.392040:0.522011:0.392040:0.512825:0.379611:0.512825:0.006215:0.006215
In adults and paediatric patients, imatin-:@0.103030:0.543346:0.475750:0.543346:0.475750:0.527590:0.103030:0.527590:0.004349:0.011738:0.004280:0.013143:0.013181:0.011699:0.003848:0.006523:0.007466:0.004291:0.013143:0.011738:0.013181:0.004280:0.013123:0.013143:0.012508:0.013181:0.003848:0.013143:0.006523:0.005792:0.003848:0.012450:0.004281:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.004280:0.003848:0.018049:0.013143:0.006523:0.003848:0.011738:0.006388
ib is indicated for CML, CML in blast crisis or :@0.084846:0.559062:0.481115:0.559062:0.481115:0.543306:0.084846:0.543306:0.003848:0.013123:0.004349:0.003848:0.007466:0.004349:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.004349:0.006042:0.012604:0.005792:0.004328:0.015644:0.017684:0.008890:0.005330:0.004331:0.015644:0.017684:0.008890:0.004333:0.003848:0.011738:0.004335:0.013123:0.003848:0.013143:0.007466:0.006523:0.004349:0.012450:0.005792:0.003848:0.007466:0.003848:0.007466:0.004349:0.012604:0.005792:0.005330
accelerated or chronic phase after inter-:@0.084846:0.574778:0.475765:0.574778:0.475765:0.559022:0.084846:0.559022:0.013143:0.012450:0.012450:0.012508:0.003848:0.012508:0.005792:0.013143:0.006523:0.012508:0.013181:0.007029:0.012604:0.005792:0.007025:0.012450:0.011738:0.005709:0.012604:0.011738:0.003848:0.012450:0.007029:0.013123:0.011738:0.013143:0.007466:0.012508:0.007043:0.013143:0.006042:0.006523:0.012508:0.005792:0.007025:0.003848:0.011738:0.006523:0.012508:0.005792:0.006388
feron-alpha therapy failure. In adult pa-:@0.084846:0.590494:0.475747:0.590493:0.475747:0.574737:0.084846:0.574738:0.006042:0.012508:0.005709:0.012604:0.011738:0.006388:0.013143:0.003848:0.013123:0.011738:0.013143:0.007870:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007870:0.006042:0.013143:0.003848:0.003848:0.011699:0.005721:0.012508:0.005330:0.017021:0.004349:0.011738:0.007870:0.013143:0.013181:0.011699:0.003848:0.006523:0.007870:0.013123:0.013143:0.149205
13 :@0.345848:0.584874:0.361385:0.584874:0.361385:0.575689:0.345848:0.575689:0.006215:0.006215:0.003107
tients, imatinib  is  indicated for patients :@0.084857:0.606209:0.481087:0.606209:0.481087:0.590454:0.084857:0.590454:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.012354:0.003848:0.018049:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.007041:0.003848:0.007466:0.005330:0.007035:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.012354:0.006042:0.012604:0.005792:0.012354:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
with:@0.084857:0.621926:0.122957:0.621926:0.122957:0.606170:0.084857:0.606170:0.015990:0.003848:0.006523:0.011738
Philadelphia-chromosome-positive:@0.153264:0.621926:0.475763:0.621926:0.475763:0.606170:0.153264:0.606170:0.011392:0.011738:0.003848:0.003848:0.013143:0.013181:0.012508:0.003848:0.013123:0.011738:0.003848:0.013143:0.006388:0.012450:0.011738:0.005721:0.012604:0.018049:0.012604:0.007466:0.012594:0.018049:0.012508:0.006388:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508
ALL (Ph+ALL) integrated with chemothera-:@0.084857:0.637642:0.475767:0.637642:0.475767:0.621886:0.084857:0.621886:0.014239:0.008890:0.008890:0.004410:0.007100:0.011392:0.011738:0.011661:0.014239:0.008890:0.008890:0.007100:0.004412:0.003848:0.011738:0.006523:0.012508:0.012950:0.005792:0.013143:0.006523:0.012508:0.013181:0.004407:0.015990:0.003848:0.006523:0.011738:0.004426:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013114:0.006388
py relapse or  Ph+ALL  as monotherapy, :@0.084857:0.653358:0.481116:0.653358:0.481116:0.637602:0.084857:0.637602:0.013123:0.010314:0.011988:0.005713:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.011988:0.012604:0.005792:0.005330:0.006642:0.011392:0.011738:0.011661:0.014239:0.008890:0.008890:0.005330:0.006637:0.013143:0.007466:0.011988:0.018049:0.012604:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330
myelodysplastic  or  myeloproliferative dis-:@0.084857:0.669074:0.475763:0.669074:0.475763:0.653319:0.084857:0.653319:0.018049:0.010314:0.012508:0.003848:0.012604:0.013181:0.010314:0.007466:0.013123:0.003848:0.013143:0.007466:0.006523:0.003848:0.012450:0.005330:0.003167:0.012604:0.005792:0.005330:0.003140:0.018049:0.010314:0.012508:0.003848:0.012604:0.013123:0.005715:0.012604:0.003848:0.003848:0.006042:0.012508:0.005792:0.013143:0.006523:0.003848:0.010660:0.012508:0.008486:0.013181:0.003848:0.007466:0.006388
ease  (MDS/MPD)  associated  with  PDGF-:@0.084857:0.684791:0.475757:0.684791:0.475757:0.669035:0.084857:0.669035:0.012508:0.013143:0.007466:0.012508:0.005330:0.004433:0.007100:0.017684:0.014316:0.009583:0.008409:0.017684:0.011392:0.014316:0.007100:0.005330:0.004435:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.004432:0.015990:0.003848:0.006523:0.011738:0.005330:0.004432:0.011392:0.014316:0.016779:0.009333:0.006388
receptor  gene  rearrangement,  systemic :@0.084857:0.700507:0.481087:0.700507:0.481087:0.684751:0.084857:0.684751:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005330:0.005979:0.012950:0.012508:0.011738:0.012498:0.005330:0.005992:0.005713:0.012508:0.013143:0.005792:0.005792:0.013143:0.011738:0.012950:0.012508:0.018049:0.012492:0.011738:0.006523:0.005330:0.005330:0.005982:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.003848:0.012450:0.005330
mastocytosis (SM) without the D816V c-Kit :@0.084857:0.716223:0.481095:0.716223:0.481095:0.700467:0.084857:0.700467:0.018049:0.013143:0.007466:0.006523:0.012604:0.012450:0.010314:0.006523:0.012604:0.007466:0.003848:0.007466:0.006177:0.007100:0.009583:0.017684:0.007100:0.006177:0.015990:0.003848:0.006523:0.011738:0.012604:0.011699:0.006523:0.006177:0.006523:0.011738:0.012508:0.006177:0.014316:0.010660:0.010660:0.010660:0.013508:0.006194:0.012450:0.006388:0.011372:0.003848:0.006523:0.005330
mutation  and  eosinophilia, hypereosino-:@0.084857:0.731939:0.475778:0.731939:0.475778:0.716184:0.084857:0.716184:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005505:0.013143:0.011738:0.013181:0.005330:0.005513:0.012508:0.012604:0.007466:0.003848:0.011738:0.012604:0.013123:0.011738:0.003848:0.003848:0.003848:0.013143:0.005330:0.010853:0.011738:0.010314:0.013123:0.012508:0.005715:0.012508:0.012604:0.007466:0.003848:0.011738:0.012604:0.006388
philic syndrome (HES) and/or chronic eo-:@0.084857:0.747656:0.475799:0.747656:0.475799:0.731900:0.084857:0.731900:0.012931:0.011545:0.003656:0.003656:0.003656:0.012257:0.008582:0.007274:0.010122:0.011545:0.012989:0.005519:0.012411:0.017857:0.012315:0.008582:0.006908:0.012950:0.010122:0.009390:0.006908:0.008582:0.012950:0.011545:0.012989:0.008217:0.012411:0.005600:0.008582:0.012257:0.011545:0.005521:0.012411:0.011545:0.003656:0.012257:0.008582:0.012315:0.012411:0.006388
sinophilic leukaemia (CEL) with FIP1-PDGF-:@0.084857:0.763372:0.475767:0.763372:0.475767:0.747616:0.084857:0.747616:0.007274:0.003656:0.011545:0.012411:0.012931:0.011545:0.003656:0.003656:0.003656:0.012257:0.006908:0.003656:0.012315:0.011507:0.009467:0.012950:0.012315:0.017857:0.003656:0.012950:0.006908:0.006908:0.015452:0.010122:0.008698:0.006908:0.006908:0.015798:0.003656:0.006331:0.011545:0.006908:0.009140:0.004156:0.011199:0.010468:0.006196:0.011199:0.014124:0.016587:0.009140:0.006388
receptor alpha rearrangement, unresected :@0.084857:0.779088:0.481133:0.779088:0.481133:0.763332:0.084857:0.763332:0.005521:0.012315:0.012257:0.012315:0.012931:0.006331:0.012411:0.005600:0.002644:0.012950:0.003656:0.012931:0.011545:0.012950:0.002644:0.005519:0.012315:0.012950:0.005600:0.005600:0.012950:0.011545:0.012758:0.012315:0.017857:0.012315:0.011545:0.006331:0.005138:0.002646:0.011507:0.011545:0.005521:0.012315:0.007274:0.012315:0.012257:0.006331:0.012315:0.013181:0.005330
and/or  metastatic  malignant  GI  stromal :@0.084857:0.794804:0.481097:0.794804:0.481097:0.779049:0.084857:0.779049:0.012950:0.011545:0.012989:0.008217:0.012411:0.005600:0.005330:0.006860:0.017857:0.012315:0.006331:0.012950:0.007274:0.006331:0.012950:0.006331:0.003656:0.012257:0.005330:0.006860:0.017857:0.012950:0.003656:0.003656:0.012758:0.011545:0.012950:0.011545:0.006331:0.005330:0.006860:0.016587:0.004156:0.005330:0.006860:0.007274:0.006331:0.005521:0.012411:0.017857:0.012950:0.003850:0.005330
tumours (GIST), adjuvant treatment follow-:@0.084857:0.810521:0.475801:0.810521:0.475801:0.794765:0.084857:0.794765:0.006331:0.011507:0.017857:0.012411:0.011507:0.005600:0.007274:0.006812:0.006908:0.016587:0.004156:0.009390:0.008005:0.006908:0.005138:0.006812:0.012950:0.012989:0.003714:0.011507:0.010468:0.012950:0.011545:0.006331:0.006812:0.006331:0.005519:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.006812:0.005850:0.012411:0.003656:0.003656:0.012411:0.015798:0.006388
ing resection of Kit-positive GIST, unresect-:@0.084857:0.826237:0.475776:0.826237:0.475776:0.810481:0.084857:0.810481:0.003656:0.011545:0.012758:0.007582:0.005521:0.012315:0.007274:0.012315:0.012257:0.006331:0.003656:0.012411:0.011545:0.007582:0.012411:0.005850:0.007582:0.011180:0.003656:0.006331:0.006196:0.012931:0.012411:0.007274:0.003656:0.006331:0.003656:0.010468:0.012315:0.007582:0.016587:0.004156:0.009390:0.006036:0.005138:0.007582:0.011507:0.011545:0.005521:0.012315:0.007274:0.012315:0.012257:0.006331:0.006388
ed  or  recurrent  and/or  metastatic  der-:@0.084857:0.841953:0.475801:0.841953:0.475801:0.826197:0.084857:0.826197:0.012315:0.012989:0.005330:0.007762:0.012411:0.005600:0.005330:0.007762:0.005521:0.012315:0.012257:0.011507:0.005600:0.005521:0.012315:0.011545:0.006331:0.005330:0.007762:0.012950:0.011545:0.012989:0.008217:0.012411:0.005600:0.005330:0.007762:0.017857:0.012315:0.006331:0.012950:0.007274:0.006331:0.012950:0.006331:0.003656:0.012257:0.005330:0.007762:0.012989:0.012315:0.005600:0.006388
matofibrosarcoma protuberans (DFSP). :@0.084857:0.857669:0.445527:0.857669:0.445527:0.841914:0.084857:0.841914:0.017857:0.012950:0.006331:0.012411:0.004589:0.004589:0.012931:0.005519:0.012411:0.007274:0.012950:0.005463:0.012257:0.012411:0.017857:0.012950:0.005138:0.012931:0.005521:0.012411:0.006331:0.011507:0.012931:0.012315:0.005600:0.012950:0.011545:0.007274:0.005138:0.006908:0.014124:0.009140:0.009390:0.011199:0.006908:0.005328:0.005330
Dasatinib is indicated for Ph+ CML in :@0.103041:0.873386:0.481131:0.873386:0.481131:0.857630:0.103041:0.857630:0.013932:0.012758:0.007081:0.012758:0.006138:0.003464:0.011353:0.003464:0.012738:0.013066:0.003464:0.007081:0.013066:0.003464:0.011353:0.012796:0.003464:0.012065:0.012758:0.006138:0.012123:0.012796:0.013066:0.005657:0.012219:0.005407:0.013066:0.011007:0.011353:0.011276:0.013066:0.015259:0.017299:0.008505:0.013066:0.003464:0.011734:0.005330
chronic phase, chronic-accelerated- or my-:@0.084857:0.889102:0.475788:0.889102:0.475788:0.873346:0.084857:0.873346:0.012065:0.011353:0.005328:0.012219:0.011353:0.003464:0.012065:0.004201:0.012738:0.011353:0.012758:0.007081:0.012123:0.004945:0.004201:0.012065:0.011353:0.005328:0.012219:0.011353:0.003464:0.012065:0.006004:0.012758:0.012065:0.012065:0.012123:0.003464:0.012123:0.005407:0.012758:0.006138:0.012123:0.012796:0.006004:0.004203:0.012219:0.005407:0.004201:0.017665:0.009929:0.006388
eloid- or lymphoid blast-phase chronic my-:@0.084857:0.904818:0.475726:0.904818:0.475726:0.889062:0.084857:0.889062:0.012123:0.003464:0.012219:0.003464:0.012796:0.006004:0.006696:0.012219:0.005407:0.006696:0.003464:0.009929:0.017665:0.012738:0.011353:0.012219:0.003464:0.012796:0.006696:0.012738:0.003464:0.012758:0.007081:0.006138:0.006004:0.012738:0.011353:0.012758:0.007081:0.012123:0.006696:0.012065:0.011353:0.005328:0.012219:0.011353:0.003464:0.012065:0.006696:0.017665:0.009929:0.006388
eloid leukaemia in adults resistant or intoler-:@0.084857:0.920534:0.475761:0.920534:0.475761:0.904779:0.084857:0.904779:0.012123:0.003464:0.012219:0.003464:0.012796:0.005646:0.003464:0.012123:0.011315:0.009275:0.012758:0.012123:0.017665:0.003464:0.012758:0.005648:0.003464:0.011353:0.005648:0.012758:0.012796:0.011315:0.003464:0.006138:0.007081:0.005648:0.005326:0.012123:0.007081:0.003464:0.007081:0.006138:0.012758:0.011353:0.006138:0.005648:0.012219:0.005407:0.005648:0.003464:0.011353:0.006138:0.012219:0.003464:0.012123:0.005407:0.006388
ant to prior therapy, including imatinib. :@0.084857:0.936251:0.436356:0.936251:0.436356:0.920495:0.084857:0.920495:0.012758:0.011353:0.006138:0.004945:0.006138:0.012219:0.004945:0.012738:0.005407:0.003464:0.012219:0.005407:0.004945:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.009929:0.004945:0.004945:0.003464:0.011353:0.012065:0.003464:0.011315:0.012796:0.003464:0.011353:0.012565:0.004945:0.003464:0.017665:0.012758:0.006138:0.003464:0.011353:0.003464:0.012738:0.005328:0.005330
Nilotinib is indicated for the treatment of :@0.524257:0.079503:0.920495:0.079503:0.920495:0.063748:0.524257:0.063748:0.014239:0.003848:0.003848:0.012604:0.006523:0.003848:0.011738:0.003848:0.013123:0.008082:0.003848:0.007466:0.008082:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.008082:0.006042:0.012604:0.005792:0.008072:0.006523:0.011738:0.012508:0.008082:0.006523:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.008072:0.012604:0.006042:0.005330
adult patients newly diagnosed with Ph+ :@0.524257:0.094942:0.920497:0.094942:0.920497:0.079186:0.524257:0.079186:0.013143:0.013181:0.011699:0.003848:0.006523:0.007947:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007947:0.011738:0.012508:0.015990:0.003848:0.010314:0.007947:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.012508:0.013181:0.007947:0.015990:0.003848:0.006523:0.011738:0.007947:0.011392:0.011738:0.011661:0.005330
CML in chronic phase, treatment of chron-:@0.524257:0.110380:0.915192:0.110380:0.915192:0.094624:0.524257:0.094624:0.015644:0.017684:0.008890:0.004464:0.003848:0.011738:0.004464:0.012450:0.011738:0.005711:0.012604:0.011738:0.003848:0.012450:0.004464:0.013123:0.011738:0.013143:0.007466:0.012508:0.005330:0.004464:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004464:0.012604:0.006042:0.004464:0.012450:0.011738:0.005709:0.012604:0.011738:0.006388
ic or accelerated Ph+ CML in adult pa-:@0.524257:0.125819:0.915167:0.125819:0.915167:0.110063:0.524257:0.110063:0.003848:0.012450:0.009217:0.012604:0.005792:0.009217:0.013143:0.012450:0.012450:0.012508:0.003848:0.012508:0.005792:0.013143:0.006523:0.012508:0.013181:0.009217:0.011392:0.011738:0.011661:0.009217:0.015644:0.017684:0.008890:0.009217:0.003848:0.011738:0.009217:0.013143:0.013181:0.011699:0.003848:0.006523:0.009217:0.013123:0.013143:0.006388
tients resistant or intolerant to at least one :@0.524257:0.141257:0.920522:0.141257:0.920522:0.125501:0.524257:0.125501:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005946:0.005713:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.006523:0.005946:0.012604:0.005792:0.005946:0.003848:0.011738:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.011738:0.006523:0.005934:0.006523:0.012604:0.005946:0.013143:0.006523:0.005946:0.003848:0.012508:0.013143:0.007466:0.006523:0.005946:0.012604:0.011738:0.012508:0.005330
prior therapy, including imatinib.:@0.524257:0.156696:0.824631:0.156696:0.824631:0.140940:0.524257:0.140940:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.005330:0.003848:0.018049:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330
4,13:@0.824604:0.151058:0.846356:0.151058:0.846356:0.141872:0.824604:0.141872:0.006215:0.003107:0.006215:0.006215
Side effects of these  agents include :@0.542424:0.172112:0.920502:0.172112:0.920502:0.156356:0.542424:0.156356:0.009583:0.003848:0.013181:0.012508:0.013412:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.013412:0.012604:0.006042:0.013412:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330:0.008070:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.013412:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005330
nausea and vomiting, fluid retention with :@0.524240:0.187551:0.920479:0.187551:0.920479:0.171795:0.524240:0.171795:0.011738:0.013143:0.011699:0.007466:0.012508:0.013143:0.007553:0.013143:0.011738:0.013181:0.007551:0.010660:0.012604:0.018049:0.003848:0.006523:0.003848:0.011738:0.012950:0.005330:0.007545:0.004666:0.004666:0.011699:0.003848:0.013181:0.007553:0.005711:0.012508:0.006523:0.012508:0.011738:0.006523:0.003848:0.012604:0.011738:0.007537:0.015990:0.003848:0.006523:0.011738:0.005330
ankle  and  peripheral oedema,  myalgias :@0.524240:0.202989:0.920481:0.202989:0.920481:0.187233:0.524240:0.187233:0.013143:0.011738:0.009660:0.003848:0.012508:0.005330:0.003779:0.013143:0.011738:0.013181:0.005330:0.003777:0.013123:0.012508:0.005792:0.003848:0.013123:0.011738:0.012508:0.005792:0.013143:0.003848:0.009121:0.012604:0.012508:0.013181:0.012508:0.018049:0.013143:0.005330:0.005330:0.003779:0.018049:0.010314:0.013143:0.003848:0.012950:0.003848:0.013143:0.007466:0.005330
and congestive heart failure.:@0.524240:0.218427:0.793366:0.218427:0.793366:0.202672:0.524240:0.202672:0.013143:0.011738:0.013181:0.005330:0.012450:0.012604:0.011738:0.012950:0.012508:0.007466:0.006523:0.003848:0.010660:0.012508:0.005330:0.011738:0.012508:0.013143:0.005792:0.006523:0.005330:0.006042:0.013143:0.003848:0.003848:0.011699:0.005698:0.012508:0.005330
4:@0.793363:0.212800:0.799578:0.212800:0.799578:0.203614:0.793363:0.203614:0.006215
Erlotinib:@0.524242:0.250348:0.604632:0.250348:0.604632:0.232533:0.524242:0.232533:0.011118:0.006842:0.005131:0.013683:0.006414:0.005131:0.012828:0.005131:0.014111
Erlotinib inhibits the EGFR and EGFR tyrosine :@0.524242:0.266930:0.920474:0.266930:0.920474:0.251174:0.524242:0.251174:0.010122:0.005600:0.003656:0.012411:0.006331:0.003656:0.011545:0.003656:0.012931:0.004782:0.003656:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.007274:0.004782:0.006331:0.011545:0.012315:0.004782:0.010122:0.016587:0.009140:0.011488:0.004780:0.012950:0.011545:0.012989:0.004782:0.010122:0.016587:0.009140:0.011488:0.004782:0.006331:0.010122:0.005519:0.012411:0.007274:0.003656:0.011545:0.012506:0.005330
kinase, preventing autophosphorylation of :@0.524242:0.282369:0.920501:0.282369:0.920501:0.266613:0.524242:0.266613:0.009467:0.003656:0.011545:0.012950:0.007274:0.012315:0.005138:0.006743:0.012931:0.005521:0.012315:0.010468:0.012315:0.011545:0.006331:0.003656:0.011545:0.012758:0.006743:0.012950:0.011507:0.006331:0.012411:0.012931:0.011545:0.012411:0.007274:0.012931:0.011545:0.012411:0.005600:0.010122:0.003656:0.012950:0.006331:0.003656:0.012411:0.011545:0.006743:0.012411:0.006040:0.005330
the kinase and thereby inhibiting the EGF-:@0.524242:0.297807:0.915128:0.297807:0.915128:0.282051:0.524242:0.282051:0.006331:0.011545:0.012315:0.006870:0.009467:0.003656:0.011545:0.012950:0.007274:0.012315:0.006870:0.012950:0.011545:0.012989:0.006870:0.006331:0.011545:0.012315:0.005519:0.012315:0.012931:0.010122:0.006870:0.003656:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.003656:0.011545:0.012758:0.006870:0.006331:0.011545:0.012315:0.006870:0.010122:0.016587:0.009140:0.006388
signalling pathway.:@0.524242:0.313246:0.700291:0.313246:0.700291:0.297490:0.524242:0.297490:0.007274:0.003656:0.012758:0.011545:0.012950:0.003656:0.003656:0.003656:0.011545:0.012758:0.004637:0.012931:0.012950:0.006331:0.011545:0.015798:0.012950:0.010122:0.005330
4,26:@0.700115:0.307618:0.721531:0.307618:0.721531:0.298432:0.700115:0.298432:0.006103:0.002995:0.006103:0.006215
 Erlotinib is used in the :@0.721424:0.313237:0.920446:0.313237:0.920446:0.297481:0.721424:0.297481:0.004637:0.010122:0.005600:0.003656:0.012411:0.006331:0.003656:0.011545:0.003656:0.012931:0.004637:0.003656:0.007274:0.004637:0.011507:0.007274:0.012315:0.012989:0.004637:0.003656:0.011545:0.004637:0.006331:0.011545:0.012506:0.005330
treatment of locally advanced or meta-:@0.524247:0.328675:0.915153:0.328675:0.915153:0.312919:0.524247:0.312919:0.006331:0.005519:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.010025:0.012411:0.005850:0.010025:0.003656:0.012411:0.012257:0.012950:0.003656:0.003656:0.010122:0.010025:0.012950:0.012989:0.010468:0.012950:0.011545:0.012257:0.012315:0.012989:0.010025:0.012411:0.005600:0.010025:0.017857:0.012315:0.006331:0.012950:0.006388
static non-small-cell lung cancer after fail-:@0.524247:0.344114:0.915176:0.344114:0.915176:0.328358:0.524247:0.328358:0.007274:0.006331:0.012950:0.006331:0.003656:0.012257:0.007004:0.011545:0.012411:0.011545:0.006196:0.007274:0.017857:0.012950:0.003656:0.003656:0.006196:0.012257:0.012315:0.003656:0.003656:0.007004:0.003656:0.011507:0.011545:0.012758:0.007004:0.012257:0.012950:0.011545:0.012257:0.012315:0.005600:0.007004:0.012950:0.005850:0.006331:0.012315:0.005600:0.007004:0.005850:0.012950:0.003656:0.003656:0.006388
ure of at least one prior chemotherapy :@0.524247:0.359552:0.920564:0.359552:0.920564:0.343796:0.524247:0.343796:0.011507:0.005521:0.012315:0.011122:0.012411:0.005850:0.011122:0.012950:0.006331:0.011122:0.003656:0.012315:0.012950:0.007274:0.006331:0.011122:0.012411:0.011545:0.012315:0.011122:0.012931:0.005600:0.003656:0.012411:0.005600:0.011122:0.012257:0.011545:0.012315:0.017857:0.012411:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010316:0.005330
regimen,  first-line  treatment  of  locally  ad-:@0.524247:0.374991:0.915170:0.374991:0.915170:0.359235:0.524247:0.359235:0.005521:0.012315:0.012758:0.003656:0.017857:0.012315:0.011545:0.005138:0.005330:0.003325:0.004589:0.004589:0.005600:0.007274:0.006331:0.006196:0.003656:0.003656:0.011545:0.012315:0.005330:0.003325:0.006331:0.005521:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.005330:0.003325:0.012411:0.005850:0.005330:0.003325:0.003656:0.012411:0.012257:0.012950:0.003656:0.003656:0.010122:0.005330:0.003323:0.012950:0.012989:0.006388
vanced or metastatic (stage IV) bronchial :@0.524247:0.390429:0.920468:0.390429:0.920468:0.374673:0.524247:0.374673:0.010468:0.012950:0.011545:0.012257:0.012315:0.012989:0.006504:0.012411:0.005600:0.006504:0.017857:0.012315:0.006331:0.012950:0.007274:0.006331:0.012950:0.006331:0.003656:0.012257:0.006504:0.006908:0.007274:0.006331:0.012950:0.012758:0.012315:0.006504:0.004156:0.013316:0.006908:0.006504:0.012931:0.005521:0.012411:0.011545:0.012257:0.011545:0.003656:0.012950:0.003850:0.005330
adenocarcinoma  demonstrating EGF-re-:@0.524247:0.405868:0.915182:0.405868:0.915182:0.390112:0.524247:0.390112:0.012950:0.012989:0.012315:0.011545:0.012411:0.012257:0.012950:0.005465:0.012257:0.003656:0.011545:0.012411:0.017857:0.012950:0.005330:0.008438:0.012989:0.012315:0.017857:0.012411:0.011545:0.007274:0.006331:0.005600:0.012950:0.006331:0.003656:0.011545:0.012758:0.013778:0.010122:0.016587:0.009140:0.006196:0.005519:0.012315:0.006388
ceptor-activated mutation in patients who :@0.524247:0.421306:0.920481:0.421306:0.920481:0.405550:0.524247:0.405550:0.012257:0.012315:0.012931:0.006331:0.012411:0.005600:0.006196:0.012950:0.012257:0.006331:0.003656:0.010468:0.012950:0.006331:0.012315:0.012989:0.005388:0.017857:0.011507:0.006331:0.012950:0.006331:0.003656:0.012411:0.011545:0.005388:0.003656:0.011545:0.005388:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.005388:0.015798:0.011545:0.012598:0.005330
have never smoked and with ECOG per-:@0.524247:0.436744:0.915195:0.436744:0.915195:0.420989:0.524247:0.420989:0.011545:0.012950:0.010468:0.012315:0.008063:0.011545:0.012315:0.010468:0.012315:0.005600:0.008063:0.007274:0.017857:0.012411:0.009467:0.012315:0.012989:0.008063:0.012950:0.011545:0.012989:0.008063:0.015798:0.003656:0.006331:0.011545:0.008063:0.010122:0.015452:0.016529:0.016587:0.008063:0.012931:0.012315:0.005600:0.006388
formance status of 0-1, and first-line treat-:@0.524247:0.452183:0.915166:0.452183:0.915166:0.436427:0.524247:0.436427:0.005850:0.012411:0.006131:0.017857:0.012950:0.011545:0.012257:0.012315:0.007389:0.007274:0.006331:0.012950:0.006331:0.011507:0.007274:0.007391:0.012411:0.005850:0.007389:0.010468:0.006196:0.010468:0.005138:0.007389:0.012950:0.011545:0.012989:0.007389:0.004589:0.004589:0.005600:0.007274:0.006331:0.006196:0.003656:0.003656:0.011545:0.012315:0.007389:0.006331:0.005519:0.012315:0.012950:0.006331:0.006388
ment of locally advanced unresectable or :@0.524247:0.467621:0.920460:0.467621:0.920460:0.451865:0.524247:0.451865:0.017857:0.012315:0.011545:0.006331:0.005657:0.012411:0.005850:0.005657:0.003656:0.012411:0.012257:0.012950:0.003656:0.003656:0.010122:0.005657:0.012950:0.012989:0.010468:0.012950:0.011545:0.012257:0.012315:0.012989:0.005657:0.011507:0.011545:0.005519:0.012315:0.007274:0.012315:0.012257:0.006331:0.012950:0.012931:0.003656:0.012315:0.005657:0.012411:0.005788:0.005330
metastatic pancreatic cancer in combina-:@0.524247:0.483060:0.915155:0.483060:0.915155:0.467304:0.524247:0.467304:0.017857:0.012315:0.006331:0.012950:0.007274:0.006331:0.012950:0.006331:0.003656:0.012257:0.004455:0.012931:0.012950:0.011545:0.012257:0.005521:0.012315:0.012950:0.006331:0.003656:0.012257:0.004455:0.012257:0.012950:0.011545:0.012257:0.012315:0.005600:0.004455:0.003656:0.011545:0.004455:0.012257:0.012411:0.017857:0.012931:0.003656:0.011545:0.012950:0.006388
tion with gemcitabine.:@0.524247:0.498498:0.731700:0.498498:0.731700:0.482742:0.524247:0.482742:0.006331:0.003656:0.012411:0.011545:0.006138:0.015798:0.003656:0.006331:0.011545:0.006138:0.012758:0.012315:0.017857:0.012257:0.003656:0.006331:0.012950:0.012931:0.003656:0.011545:0.012315:0.005330
4,13:@0.731479:0.492844:0.752894:0.492844:0.752894:0.483659:0.731479:0.483659:0.006103:0.002995:0.006103:0.006215
 Its side effects in-:@0.752787:0.498463:0.915172:0.498463:0.915172:0.482707:0.752787:0.482707:0.006138:0.004156:0.006331:0.007274:0.006138:0.007274:0.003656:0.012989:0.012315:0.006138:0.012315:0.005905:0.005850:0.012315:0.012257:0.006331:0.007274:0.006138:0.003656:0.011545:0.006388
clude  hypertension,  diarrhoea,  skin  rash, :@0.524245:0.513902:0.920498:0.513902:0.920498:0.498146:0.524245:0.498146:0.012257:0.003656:0.011507:0.012989:0.012315:0.005330:0.005952:0.011545:0.010122:0.012931:0.012315:0.005600:0.006331:0.012315:0.011545:0.007274:0.003656:0.012411:0.011545:0.005138:0.005330:0.005952:0.012989:0.003656:0.012950:0.005600:0.006150:0.011545:0.012411:0.012315:0.012950:0.005138:0.005330:0.005954:0.007274:0.009467:0.003656:0.011545:0.005330:0.005952:0.005600:0.012950:0.007274:0.011545:0.005326:0.005330
anorexia and interstitial lung disease.:@0.524245:0.529340:0.859542:0.529340:0.859542:0.513584:0.524245:0.513584:0.012950:0.011545:0.012411:0.005521:0.012315:0.009044:0.003656:0.012950:0.005138:0.012950:0.011545:0.012989:0.005138:0.003656:0.011545:0.006331:0.012315:0.005600:0.007274:0.006331:0.003656:0.006331:0.003656:0.012950:0.003656:0.005138:0.003656:0.011507:0.011545:0.012758:0.005138:0.012989:0.003656:0.007274:0.012315:0.012950:0.007274:0.012315:0.005330
4:@0.859342:0.523715:0.865557:0.523715:0.865557:0.514530:0.859342:0.514530:0.006215
Gefitinib:@0.524242:0.561264:0.610619:0.561264:0.610619:0.543449:0.524242:0.543449:0.017960:0.013683:0.005559:0.005559:0.006414:0.005131:0.012828:0.005131:0.014111
Gefitinib  has  a  similar  mechanism  of  ac-:@0.524242:0.577846:0.915149:0.577846:0.915149:0.562090:0.524242:0.562090:0.016779:0.012508:0.004686:0.004686:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.003346:0.011738:0.013143:0.007466:0.005330:0.003348:0.013143:0.005330:0.003344:0.007466:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.005330:0.003358:0.018049:0.012508:0.012450:0.011738:0.013143:0.011738:0.003848:0.007466:0.018049:0.005330:0.003350:0.012604:0.006042:0.005330:0.003340:0.013143:0.012450:0.006388
tion to erlotinib and is indicated as first-line :@0.524242:0.593284:0.920485:0.593284:0.920485:0.577528:0.524242:0.577528:0.006523:0.003848:0.012604:0.011738:0.005043:0.006523:0.012604:0.005043:0.012508:0.005792:0.003848:0.012604:0.006523:0.003848:0.011738:0.003848:0.013123:0.005049:0.013143:0.011738:0.013181:0.005051:0.003848:0.007466:0.005057:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005053:0.013143:0.007466:0.005055:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.003848:0.003848:0.011738:0.012508:0.005330
treatment of patients with metastatic non-:@0.524242:0.608723:0.915176:0.608723:0.915176:0.592967:0.524242:0.592967:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004680:0.012604:0.006042:0.004684:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004695:0.015990:0.003848:0.006523:0.011738:0.004695:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.004695:0.011738:0.012604:0.011738:0.006388
small-cell  lung cancer (NSCLC) with tu-:@0.524242:0.624161:0.915169:0.624161:0.915169:0.608405:0.524242:0.608405:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.005944:0.003848:0.011699:0.011738:0.012950:0.011257:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.011257:0.007100:0.014239:0.009583:0.015644:0.008890:0.015644:0.007100:0.011257:0.015990:0.003848:0.006523:0.011738:0.011257:0.006523:0.011699:0.006388
mours having epidermal growth factor re-:@0.524242:0.639600:0.915155:0.639600:0.915155:0.623844:0.524242:0.623844:0.018049:0.012604:0.011699:0.005792:0.007466:0.005600:0.011738:0.013143:0.010660:0.003848:0.011738:0.012950:0.005609:0.012508:0.013123:0.003848:0.013181:0.012508:0.006329:0.018049:0.013143:0.003848:0.005609:0.012950:0.005711:0.012604:0.015990:0.006523:0.011738:0.005598:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.005594:0.005713:0.012508:0.006388
ceptor  (EGFR) exon  19 deletions or  exon :@0.524242:0.655038:0.920485:0.655038:0.920485:0.639282:0.524242:0.639282:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005330:0.002911:0.007100:0.010314:0.016779:0.009333:0.011680:0.007100:0.008255:0.012508:0.009236:0.012604:0.011738:0.005330:0.002913:0.010660:0.010660:0.008255:0.013181:0.012508:0.003848:0.012508:0.006523:0.003848:0.012604:0.011738:0.007466:0.008255:0.012604:0.005792:0.005330:0.002915:0.012508:0.009236:0.012604:0.011738:0.005330
21 (L858R) substitution mutations.:@0.524242:0.670476:0.828291:0.670476:0.828291:0.654721:0.524242:0.654721:0.010660:0.010660:0.005330:0.007100:0.008890:0.010660:0.010660:0.010660:0.011680:0.007100:0.005330:0.007466:0.011699:0.013123:0.007466:0.006523:0.003848:0.006523:0.011699:0.006523:0.003848:0.012604:0.011738:0.005330:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330
139:@0.828296:0.664840:0.846941:0.664840:0.846941:0.655654:0.828296:0.655654:0.006215:0.006215:0.006215
Lapatinib :@0.524242:0.702388:0.625585:0.702388:0.625585:0.684573:0.524242:0.684573:0.009407:0.014111:0.014111:0.014111:0.006414:0.005131:0.012828:0.005131:0.014111:0.005987
Lapatinib, a TKI, is indicated as combina-:@0.524242:0.718970:0.915170:0.718970:0.915170:0.703215:0.524242:0.703215:0.008890:0.013143:0.013123:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.007023:0.013143:0.007023:0.008197:0.011372:0.004349:0.005330:0.007023:0.003848:0.007466:0.007023:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.007023:0.013143:0.007466:0.007023:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006388
tion  therapy for  HER2-positive  metastatic :@0.524242:0.734409:0.920497:0.734409:0.920497:0.718653:0.524242:0.718653:0.006523:0.003848:0.012604:0.011738:0.005330:0.003583:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.008928:0.006042:0.012604:0.005792:0.005330:0.003583:0.013143:0.010314:0.011680:0.010660:0.006388:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012525:0.005330:0.003589:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
breast cancer.  Lapatinib combinations :@0.524242:0.749847:0.920472:0.749841:0.920472:0.734086:0.524242:0.734091:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.011161:0.012450:0.013143:0.011738:0.012450:0.012508:0.004376:0.005330:0.012432:0.011161:0.008890:0.013143:0.013123:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.011161:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:-0.528357
50:@0.665872:0.744222:0.678302:0.744222:0.678302:0.735037:0.665872:0.735037:0.006215:0.006215
include::@0.524251:0.765280:0.598854:0.765280:0.598854:0.749524:0.524251:0.749524:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005330
50:@0.598844:0.759658:0.611274:0.759658:0.611274:0.750473:0.598844:0.750473:0.006215:0.006215
n :@0.524242:0.778181:0.537570:0.778181:0.537570:0.769741:0.524242:0.769741:0.009762:0.003566
 :@0.554542:0.778181:0.558108:0.778181:0.558108:0.769741:0.554542:0.769741:0.003566
Use with capecitabine in patients who :@0.554545:0.781301:0.916398:0.781301:0.916398:0.765545:0.554545:0.765545:0.012604:0.007466:0.012508:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.012450:0.013143:0.013123:0.012508:0.012450:0.003848:0.006523:0.013143:0.013123:0.003848:0.011738:0.012508:0.005330:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.011738:0.012604:0.005330
have received prior therapy, including :@0.554545:0.796739:0.917549:0.796739:0.917549:0.780983:0.554545:0.780983:0.011738:0.013143:0.010660:0.012508:0.005330:0.005711:0.012508:0.012450:0.012508:0.003848:0.010660:0.012508:0.013181:0.005330:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.005330
an anthracycline, a taxane and :@0.554545:0.812177:0.858132:0.812177:0.858132:0.796422:0.554545:0.796422:0.013143:0.011738:0.005330:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.005330:0.005330:0.013143:0.005330:0.006523:0.013143:0.009236:0.013143:0.011738:0.012508:0.005330:0.013143:0.011738:0.013181:0.005330
trastuzumab :@0.554545:0.827616:0.675214:0.827616:0.675214:0.811860:0.554545:0.811860:0.006523:0.005792:0.013143:0.007466:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330
n :@0.524242:0.840512:0.537570:0.840512:0.537570:0.832071:0.524242:0.832071:0.009762:0.003566
 :@0.554542:0.840512:0.558108:0.840512:0.558108:0.832071:0.554542:0.832071:0.003566
Use with letrozole in postmenopausal :@0.554545:0.843631:0.902806:0.843631:0.902806:0.827875:0.554545:0.827875:0.012604:0.007466:0.012508:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.003848:0.012508:0.006523:0.005709:0.012604:0.008178:0.012592:0.003848:0.012508:0.005330:0.003848:0.011738:0.005330:0.013123:0.012604:0.007466:0.006523:0.018049:0.012508:0.011738:0.012594:0.013123:0.013143:0.011699:0.007466:0.013143:0.003848:0.005330
women in whom hormonal therapy is :@0.554545:0.859069:0.905857:0.859069:0.905857:0.843313:0.554545:0.843313:0.015990:0.012604:0.018049:0.012508:0.011738:0.005330:0.003848:0.011738:0.005330:0.015990:0.011738:0.012604:0.018049:0.005330:0.011738:0.012604:0.006296:0.018049:0.012604:0.011738:0.013143:0.003848:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003848:0.007466:0.005330
indicated :@0.554545:0.874508:0.650295:0.874508:0.650295:0.858752:0.554545:0.858752:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330
Side effects of lapatinib  combination :@0.542422:0.889946:0.920474:0.889946:0.920474:0.874190:0.542422:0.874190:0.009583:0.003848:0.013181:0.012508:0.012334:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.012334:0.012604:0.006042:0.012334:0.003848:0.013143:0.013123:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.007023:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
therapy  include diarrhoea,  palmar-plan-:@0.524238:0.905384:0.915138:0.905384:0.915138:0.889628:0.524238:0.889628:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004378:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.009717:0.013181:0.003848:0.013143:0.005792:0.006346:0.011738:0.012604:0.012508:0.013143:0.005330:0.005330:0.004372:0.013123:0.013143:0.003848:0.018049:0.013143:0.005792:0.006388:0.013123:0.003848:0.013143:0.011738:0.006388
tar erythrodysesthesia, nausea and vomit-:@0.524238:0.920823:0.915146:0.920823:0.915146:0.905067:0.524238:0.905067:0.006523:0.013143:0.005792:0.005734:0.012508:0.005792:0.010314:0.006523:0.011738:0.005713:0.012604:0.013181:0.010314:0.007466:0.012508:0.007466:0.006523:0.011738:0.012508:0.007466:0.003848:0.013143:0.005330:0.005734:0.011738:0.013143:0.011699:0.007466:0.012508:0.013143:0.005734:0.013143:0.011738:0.013181:0.005734:0.010660:0.012604:0.018049:0.003848:0.006523:0.006388
ing, rash and fatigue.:@0.524238:0.936261:0.722339:0.936261:0.722339:0.920505:0.524238:0.920505:0.003848:0.011738:0.012950:0.005330:0.005330:0.005792:0.013143:0.007466:0.011738:0.005330:0.013143:0.011738:0.013181:0.005330:0.006042:0.013143:0.006523:0.003848:0.012950:0.011699:0.012508:0.005330
50:@0.722322:0.930625:0.734752:0.930625:0.734752:0.921439:0.722322:0.921439:0.006215:0.006215
Small-molecule kinase inhibitors:@0.557736:0.038601:0.914535:0.038601:0.914535:0.019343:0.557736:0.019343:0.011712:0.022060:0.016063:0.004704:0.004704:0.007808:0.022060:0.015405:0.004704:0.015287:0.015216:0.014299:0.004704:0.015287:0.006515:0.011806:0.004704:0.014346:0.016063:0.009125:0.015287:0.006515:0.004704:0.014346:0.014346:0.004704:0.016040:0.004704:0.007973:0.015405:0.007079:0.009125